Rita Nahta

7.8k citations

66 papers · 5.5k indexed · 2 hit papers · h-index 35

Impact in

Oncology top 0.5%
- HER2/EGFR in Cancer Research
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
- Cancer-related Molecular Pathways
Radiology, Nuclear Medicine and Imaging top 0.5%
- Monoclonal and Polyclonal Antibodies Research

Papers in

Oncology 50
- HER2/EGFR in Cancer Research 40
- Peptidase Inhibition and Analysis 10
- Cancer-related Molecular Pathways 7
Radiology, Nuclear Medicine and Imaging 28
- Monoclonal and Polyclonal Antibodies Research 28

Co-authors: Francisco J. Esteva Mien‐Chie Hung Gabriel N. Hortobágyi Linda X.H. Yuan Dihua Yu Ruth O’ReganBing ZhangRyûji Kobayashi
Journals: Cancer Research (5 papers)Molecular Cancer Therapeutics (4 papers)Biochemical Pharmacology (4 papers)Current Medicinal Chemistry (3 papers)Oncotarget (3 papers)
Partner nations: United States France China

In The Last Decade

Rita Nahta

66 papers receiving 5.4k citations

Hit Papers

align trajectories log scale

Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer 2006 · 696 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2006 Nature Clinical Practice Oncology
2005 Cancer Research

Peers

Countries citing papers authored by Rita Nahta

Since Specialization

Citations

This map shows the geographic impact of Rita Nahta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rita Nahta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rita Nahta more than expected).

Fields of papers citing papers by Rita Nahta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rita Nahta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rita Nahta. The network helps show where Rita Nahta may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Rita Nahta, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Rita Nahta Line = papers co-authored together Rita Nahta links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Using Online Cancer Genomics Databases to Provide Teaching Resources for Pharmacy Education American Journal of Pharmaceutical Education ·Yasuhiro Sekimoto, Antti Riikonena, Rita Nahta	2021	1
2	Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2–Directed Chemotherapy in HER2-Positive Breast Cancer Clinical Breast Cancer ·Jane Meisel, Jing Zhao, Aili Suo, Chao Zhang, Zhimin Wei, Caitlin Taylor, Ritu Aneja, Uma Krishnamurti, Zaibo Li, Rita Nahta, Ruth O’Regan, Xiaoxian Li	2019	30
3	ABP 980: promising trastuzumab biosimilar for HER2-positive breast cancer Expert Opinion on Biological Therapy ·Elisavet Paplomata, Rita Nahta	2018	4
4	Targeting forkhead box M1 transcription factor in breast cancer Biochemical Pharmacology ·Ruth O’Regan, Rita Nahta	2018	32
5	Systemic therapy for early‐stage HER2‐positive breast cancers: Time for a less‐is‐more approach? Cancer ·Elisavet Paplomata, Rita Nahta, Ruth O’Regan	2014	15
6	IGF-1R peptide vaccines/mimics inhibit the growth of BxPC3 and JIMT-1 cancer cells and exhibit synergistic antitumor effects with HER-1 and HER-2 peptides OncoImmunology ·Kevin Foy, Megan Miller, Jay Overholser, Siobhan Donnelly, Rita Nahta, Pravin T. P. Kaumaya	2014	8
7	Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers Breast Cancer Research and Treatment ·Rita Nahta, Ruth O’Regan	2012	67
8	Selective Inhibition of HER2-Positive Breast Cancer Cells by the HIV Protease Inhibitor Nelfinavir JNCI Journal of the National Cancer Institute ·Joong Sup Shim, Rajini Rao, Kristin Beebe, Len Neckers, 罗冉, Rita Nahta, Jun O. Liu	2012	66
9	Pharmacological Strategies to Overcome HER2 Cross-Talk and Trastuzumab Resistance Current Medicinal Chemistry ·Rita Nahta	2012	59
10	Growth differentiation factor 15 stimulates rapamycin-sensitive ovarian cancer cell growth and invasion Biochemical Pharmacology ·Yesmin, Jayashree Joshi, Rita Nahta	2012	55
11	Overcoming Trastuzumab Resistance in Breast Cancer by Targeting Dysregulated Glucose Metabolism Cancer Research ·Yuhua Zhao, Hao Liu, Zixing Liu, Yan Ding, Susan P. LeDoux, Glenn L. Wilson, Richard Voellmy, Yifeng Lin, Wensheng Lin, Rita Nahta, Bolin Liu, Øystein Fodstad, Jieqing Chen, Yun Wu, Janet E. Price, Ming Tan	2011	240
12	Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells Biochemical Pharmacology ·Jayashree Joshi, Nicole Brown, Yesmin, Rita Nahta	2011	58
13	In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells Cancer Chemotherapy and Pharmacology ·Tuba Ozbay, Donald L. Durden, Tongrui Liu, Ruth O’Regan, Rita Nahta	2009	36
14	Personalizing HER2-Targeted Therapy in Metastatic Breast Cancer Beyond HER2 Status: What We Have Learned from Clinical Specimens Current pharmacogenomics and personalized medicine (Online) ·Rita Nahta, Isabelle Roussel, Tuba Ozbay, Alfred Hinsche	2009	51
15	Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: a potential treatment strategy Molecular Cancer Therapeutics ·Hiroaki Itamochi, Junzo Kigawa, Yasunobu Kanamori, Tetsuro Oishi, Jackylyn E. Baguhin, Rita Nahta, Francisco J. Esteva, Nour Sneige, Naoki Terakawa, Naoto T. Ueno	2007	21
16	Trastuzumab: triumphs and tribulations Oncogene ·Rita Nahta, Francisco J. Esteva	2007	261
17	HER-2-targeted therapy: lessons learned and future directions. PubMed ·Rita Nahta, Francisco J. Esteva	2003	143
18	Novel pharmacological approaches in the treatment of breast cancer Expert Opinion on Investigational Drugs ·Rita Nahta, Gabriel N. Hortobágyi, Francisco J. Esteva	2003	2
19	Bcl-2 antisense oligonucleotides: a potential novel strategy for the treatment of breast cancer Seminars in Oncology ·Rita Nahta	2003	58
20	Rate-limiting effects of Cyclin D1 in transformation by ErbB2 predicts synergy between herceptin and flavopiridol. PubMed ·Rita Nahta, J. Dirk Iglehart, Bettina Kempkes, Emmett V. Schmidt	2002	42

About Rita Nahta

Rita Nahta is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging, Cancer Research, Molecular Biology and Rheumatology, having authored 66 papers that have together received 5.5k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (40 papers), Monoclonal and Polyclonal Antibodies Research (28 papers), Peptidase Inhibition and Analysis (10 papers), PI3K/AKT/mTOR signaling in cancer (8 papers), Glycosylation and Glycoproteins Research (7 papers), Cancer-related Molecular Pathways (7 papers), Breast Cancer Treatment Studies (6 papers) and GDF15 and Related Biomarkers (5 papers). The work is most often cited by research in Oncology (3.4k citations), Radiology, Nuclear Medicine and Imaging (2.0k citations), Cancer Research (896 citations), Immunology and Allergy (263 citations) and Molecular Biology (2.8k citations). Rita Nahta has collaborated with scholars based in United States, France and China. Frequent co-authors include Francisco J. Esteva, Mien‐Chie Hung, Gabriel N. Hortobágyi, Linda X.H. Yuan, Dihua Yu, Ruth O’Regan, Bing Zhang, Ryûji Kobayashi, Tuba Ozbay and Naoto T. Ueno. Their work appears in journals such as Cancer Research, Molecular Cancer Therapeutics, Biochemical Pharmacology, Current Medicinal Chemistry and Oncotarget.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact